|Bid||0.00 x 1000|
|Ask||0.00 x 3000|
|Day's Range||1.49 - 1.66|
|52 Week Range||0.60 - 6.80|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.00|
NEW YORK, June 20, 2018 (GLOBE NEWSWIRE) -- via NetworkWire - Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Oragenics Inc. (OGEN). The in-depth 29-page initiation report includes detailed information on the Oragenics's business model, services, industry, valuation, management, and risks. The full research report is available here.
Oragenics, Inc. (NYSE American: OGEN) (the “Company”), a clinical stage biotechnology company, today announced the publication of a research paper entitled “OG716: designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections” in PLOS ONE, a peer-reviewed open access scientific journal published by the Public Library of Science. Researchers sought to discover a lead candidate for the treatment of Clostridium difficile (C. difficile) based on a second-generation library of over 300 variants of the lantibiotic Mutacin 1140 (MU1140). MU1140 remains an attractive lantibiotic due to its novel mechanism of action that may limit the development of drug resistance.
We are initiating coverage of Oragenics, Inc. (OGEN) with a $7.00 valuation. Oragenics is a biopharmaceutical company developing a new treatment for oral mucositis (OM) and a novel class of antibiotics. AG013 is the company’s lead product for the treatment of OM, a painful inflammation and ulceration of the lining of the mouth, throat, and esophagus that is one of the most common side effects of cancer chemotherapy and radiation treatment.
Alan Joslyn took the reins as CEO of Oragenics Inc’s (AMEX:OGEN) and grew market cap to US$8.52M recently. Understanding how CEOs are incentivised to run and grow their company isRead More...
NEW YORK, NY / ACCESSWIRE / May 31, 2018 / Oragenics and Sigma Labs were both big winners in the biotech arena on Wednesday. Shares of Oragenics climbed higher after announcing positive results from its interim safety analysis on patients from its Phase 2 clinical trial of AG013. AG013 is a promising product for the prevention of oral mucositis in cancer patients.
Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced positive results from its interim safety analysis as requested by FDA on patients from its Phase 2 clinical trial of AG013 for the treatment of OM. The study provides information that, we believe, likely indicates that the overall incidence of severe OM is less than would be anticipated in the general population. Safety was evaluated on the basis of treatment-emergent adverse events, vital signs, weight, physical examinations, clinical laboratory assessments and the presence of AG013 in whole blood.
Stock Research Monitor: MBRX, OGEN, and OTIC LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want a free Stock Review on NKTR sign up now at www.wallstequities.com/registration . On Friday, May 25, 2018, ...
Among other things, the patent covers the unique variants of the lantibiotic 1140 (MU1140) and other lantibiotics with improved pharmacological properties and structural features as well as the methods of using these compositions to treat and prevent infections, diseases, and colonization by one or more types of bacteria. “In recent years, antibiotic resistant bacteria have been on the rise, affecting millions of people worldwide and resulting in an increasingly large burden on the healthcare system. Lantibiotics serve as an important class of antibiotics with the potential to serve in the treatment of problematic infections caused by Gram-positive bacteria, while also potentially limiting the development of drug resistance,” Alan Joslyn, chief executive officer and president of Oragenics, said.
In this analysis, my focus will be on developing a perspective on Oragenics Inc’s (AMEX:OGEN) latest ownership structure, a less discussed, but important factor. Ownership structure has been found toRead More...
For Oragenics Inc’s (AMEX:OGEN) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. OGEN is exposed toRead More...
Florida-based biopharmaceutical company Oragenics, Inc. today announced that it has entered into a securities purchase agreement with certain new institutional investors providing for the purchase and sale of 900,000 shares of common stock at a price of $2.00 per share in a registered direct offering, resulting in total gross proceeds of approximately $1.8 million.
Oragenics, Inc. , a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced that it has completed enrollment of the interim analysis cohort of 20 patients in its Phase 2 clinical trial of AG013 for the treatment of oral mucositis .
Oragenics, Inc. , a clinical stage biotechnology company, today announced the publication of a research paper entitled “Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium difficile Infection” in the peer reviewed journal, Frontiers in Microbiology, the largest microbiology journal in the world.
After looking at Oragenics Inc’s (AMEX:OGEN) latest earnings announcement (31 December 2017), I found it useful to revisit the company’s performance in the past couple of years and assess thisRead More...
NEW YORK, NY / ACCESSWIRE / March 6, 2018 / Oragenics, Inc. (NYSE American: OGEN) will be presenting at this year's MicroCap Conference on April 9 th and 10 th in New York City. CONFERENCE OVERVIEW AND ...
Oragenics, Inc. today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2017, which was filed on February 16, 2018 with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included a going concern emphasis of matter paragraph....
Florida-based biopharmaceutical company Oragenics, Inc. today announced a reverse split of its common stock, $0.001 par value, at a ratio of 1 for 10, effective January 19, 2018 .
Assessing Oragenics Inc’s (AMEX:OGEN) past track record of performance is a valuable exercise for investors. It enables us to reflect on whether the company has met or exceed expectations, whichRead More...
Florida-based biopharmaceutical company Oragenics, Inc. today announced receipt of notification from the NYSE American LLC that the Company has regained compliance with the Exchange’s listing requirements.
Oragenics, Inc. , a clinical stage biotechnology company, today announced that it has completed a private placement of $3.3 million of Non-Voting Series B Convertible Preferred Stock with four existing shareholders who are accredited investors including an entity affiliated with a director of the Company .
Oragenics Inc (AMEX:OGEN) is a small-cap stock with a market capitalization of USD $17.25M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, theyRead More...
Oragenics Inc (AMEX:OGEN), a USD$23.65M small-cap, operates in the healthcare industry, which continues to be affected by the sustained economic uncertainty and structural trends, such as an aging population, impactingRead More...
Oragenics, Inc. , a leader in the development of novel antibiotics against infectious diseases and innovative treatments for oral mucositis, today announced that it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, being held on September 10-12, 2017 at The Lotte New York Palace Hotel in New York City.
Oragenics, Inc. , a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced that the first patient has been dosed in its Phase 2 clinical trial of AG013 for the treatment of oral mucositis .
On a per-share basis, the Tampa, Florida-based company said it had a loss of 2 cents. In the final minutes of trading on Monday, the company's shares hit 36 cents. A year ago, they were trading at 71 cents. ...